Intelligent Bio Solutions Reports 38% Revenue Growth and 778bps Gross Margin Expansion
INBS has more than doubled off its 52-week low of $1.52.
Summary
Intelligent Bio Solutions reported fiscal 2026 revenue of $4.2 million, up 38%, with gross margin expanding 778 basis points to 48.63%. The company's FDA 510(k) submission is on track for the second half of 2026.
Key Events · Earnings and Guidance · INBS
-
Record Revenue and Margin Expansion
Full-year revenue reached $4,215,175, up 38% year-over-year, while gross profit grew 64% to $2,049,994. Gross margin expanded 778 basis points to 48.63%.
-
Installed Base and Cartridge Growth
Reader installed base grew 22% to 1,886 units, and consumable cartridge sales grew 35% to 106,500 units, indicating deepening utilization among 502 active customers.
-
FDA 510(k) Submission Timeline
All clinical data collection is complete, and the FDA 510(k) submission is on track for the second half of calendar 2026, supporting planned U.S. market entry.
-
Going Concern and Net Loss
The company reported a net loss of $12.4 million and a going concern warning, but cash and cash equivalents increased to $3.99 million from $1.02 million year-over-year.
Analysis · INBS · Industrial Applications And Services
Record annual revenue of $4.2 million, up 38% year-over-year, came with gross margin expanding to 48.63% from 40.85%. The razor-razorblade model is scaling: reader installed base grew 22% to 1,886 units, and consumable cartridge sales grew 35% to 106,500 units, outpacing hardware growth and confirming deepening utilization. The FDA 510(k) submission remains on track for the second half of calendar 2026, a key catalyst for U.S. market entry. Against a going concern warning and a $12.4 million net loss, these operational improvements show the business is gaining traction, though profitability remains distant.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.4% of the 1487 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBS was trading at $3.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $1.52 to $24.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.